Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Motegrity (prucalopride) is indicated for the treatment of chronic idiopathic constipation (CIC) in adults.
• This summary is based on the review of eight systematic review(s)/meta-analysis(es). ^[1-8]
• Postoperative Return of Bowel Function: Prucalopride significantly reduced the time to stool (mean difference: 36.82 hours, 95% CI: 59.4 to 14.24 hours lower). No statistically significant differences were observed for time to flatus, time to oral tolerance, incidence of PPOI, or length of stay (very low certainty evidence).
• Gastroparesis: Prucalopride and other 5-HT4 agonists significantly improved Gastroparesis Cardinal Symptom Index (GCSI) scores (mean difference: 4.283, 95% CI: 1.380 to 7.186, p<0.05) and gastric emptying time (GET) (mean difference: 2.534, 95% CI: 1.695 to 3.373, p<0.05).
• Chronic Idiopathic Constipation (CIC): Prucalopride significantly increased the frequency of spontaneous bowel movements (SBMs) per week across different doses: 1mg (OR: 2.40, 95% CI: 1.32 to 4.37), 2mg (OR: 2.55, 95% CI: 1.93 to 3.36), and 4mg (OR: 2.51, 95% CI: 1.92 to 3.28).
• No significant differences in postoperative complications and adverse events were observed in individual studies (very low certainty evidence).
• In gastroparesis, pooled rates of total adverse events were higher with 5-HT4 agonists (mean difference: 6.975, 95% CI: 1.042 to 46.684, p<0.05), though diarrhea, abdominal pain, and headaches were comparable to placebo.
• In chronic idiopathic constipation, treatment-emergent adverse events (TEAEs) were significantly higher with prucalopride at 2mg (RR 1.20, 95% CI 1.09 to 1.33) and 4mg (RR 1.14, 95% CI 1.07 to 1.22), but not significant at 1mg (RR 1.17, 95% CI 0.94 to 1.44).
• There is no population type or subgroup information available in the reviewed studies.